Carfilzomib

1 Drug classified under this active ingredient

Proteasome Inhibitor. Carfilzomib 60 mg/vial.
Vial with pwder. for reconstr. 1X10,30,60 mg: In combination with Lenalidomide and Dexamethasone: admin. this drug 20/27 mg/m² twice/w in 28 d cycles. Discont. after cycle 18. Contin. lenalidomide and dexamethasone until dis. progress. or unaccept. tox. occurs. Combin. with dexamethasone: once/w 20/70 mg/m² regimen or 2/w 20/56 mg/m² regimen. Combin. with Daratumumab (I.V. or S.C.) and Dexamethasone: twice/w 20/56 mg/m² regimen or once/w 20/70 mg/m² regimen. As monotherapy: 20/27 mg/m² twice/w regimen. See full prescr. details.
For adlt. pts. with relapsed or refract. multiple myeloma who have received 1-3 prior lines of ther. in combin. with:
o Lenalidomide and dexamethasone; or
o Dexamethasone; or
o Daratumumab (I.V. or S.C.) and dexamethasone.
-as a sgle. agent for the tmt. of multiple myeloma  pts. who received at least 2 prior ther. incl. bortezomib and an immunomodul. agent and demonstr. dis. progr. on or within 60 days of complet. of the last ther. Approval is based on resp. rate. Clin. benefit, such as improv. in survival or sympt. has not been verified.
C/I: Hypersens.